AI assistant
ABBOTT LABORATORIES — Director's Dealing 2022
Feb 24, 2022
29777_dirs_2022-02-23_9a9bfc35-b272-44fb-867d-fcf92c4be974.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2022-02-18
Reporting Person: Moreland Mary K (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-18 | Common shares without par value | A | 15813 | — | Acquired | 88158 | Direct |
| 2022-02-22 | Common shares without par value | F | 793 | $116.79 | Disposed | 87365 | Direct |
| 2021-02-22 | Common shares without par value | S | 400 | $119.3067 | Disposed | 86965 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-18 | Option (right to buy) | $117.58 | A | 73696 | Acquired | 2032-02-17 | Common Shares (73696) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 10986 | Indirect |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.